IGC Pharma (IGC) Stock Price, News & Analysis

Company Overview

IGC Pharma (NYSEMKT:IGC) is a clinical-stage biopharmaceutical company headquartered in Montreal, Canada, focused on the development of next-generation immunotherapies for oncology and supportive care products. Since its founding in 2015, the company has leveraged a proprietary hydrogel delivery platform to enhance the local and sustained release of active agents within the tumor microenvironment. This approach aims to improve treatment efficacy while reducing systemic toxicity, positioning IGC Pharma as a promising innovator in the immuno-oncology field.

The company’s pipeline includes multiple lead programs in solid tumors and hematological malignancies, where its implantable polymer matrices are designed to deliver cytokines, checkpoint inhibitors, and chemotherapeutic agents directly to the tumor site. In preclinical studies, these formulations have demonstrated enhanced immune cell infiltration and tumor regression. In parallel, IGC Pharma is advancing supportive care candidates to manage chemotherapy-induced side effects such as oral mucositis, leveraging the same delivery technology to promote localized healing and patient comfort.

IGC Pharma serves a global market, conducting clinical trials across North America, Europe and Asia Pacific regions. The company has established strategic partnerships with research centers and academic institutions to accelerate clinical development and expand its geographic footprint. In addition to its in-house research and manufacturing capabilities in Quebec, IGC Pharma maintains collaborative agreements for regulatory submissions and distribution with specialized contract organizations in Europe and China.

Under the leadership of President and Chief Executive Officer Michel Gagnon, IGC Pharma’s management team brings together expertise in oncology research, pharmaceutical development and regulatory affairs. Chief Scientific Officer Dr. Sylvie Tremblay oversees the translation of novel immunomodulatory concepts into clinical candidates, while Chief Financial Officer Nathalie Fortier supports strategic financing and corporate governance. Together, the leadership team is focused on advancing IGC Pharma’s unique delivery platform through Phase 1 and 2 trials, with the goal of bringing new treatment options to patients with limited therapeutic alternatives.

Key Stats

• Today's Range: $0.32 to $0.34
• 50-Day Range: $0.29 to $0.42
• 52-Week Range: $0.25 to $0.63
• Volume: 214,616 shs
• Average Volume: 835,555 shs
• Market Capitalization: $33.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.88
• Consensus Rating: Buy

IGC Pharma Stock Analysis - MarketRank™

IGC Pharma scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

IGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

IGC Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for IGC Pharma are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IGC Pharma is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IGC Pharma is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IGC Pharma has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IGC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IGC Pharma does not currently pay a dividend.

Dividend Growth

IGC Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for IGC.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for IGC Pharma this week, compared to 1 article on an average week.

Search Interest

7 people have searched for IGC on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IGC Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.48% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.87% of the stock of IGC Pharma is held by institutions.

IGC Stock Analysis - Frequently Asked Questions

How have IGC shares performed this year?

IGC Pharma's stock was trading at $0.3360 at the beginning of 2025. Since then, IGC shares have increased by 23.8% and is now trading at $0.4160.

How were IGC Pharma's earnings last quarter?

IGC Pharma, Inc. (NYSEMKT:IGC) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The company earned $0.41 million during the quarter, compared to the consensus estimate of $0.29 million. IGC Pharma had a negative trailing twelve-month return on equity of 122.44% and a negative net margin of 714.16%.

How do I buy shares of IGC Pharma?

Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IGC Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IGC Pharma investors own include Jiuzi (JZXN), Plug Power (PLUG), Avalon GloboCare (ALBT), Ainos (AIMD), Aethlon Medical (AEMD), Aditxt (ADTX) and Adial Pharmaceuticals (ADIL).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 7/10/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEMKT
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEMKT:IGC
• CIK: 1326205
• Web: igcpharma.com
• Phone: (301) 983-0998
• Fax: 240-465-0273
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IGC Pharma: $3.88
• High Price Target: $4.25
• Low Price Target: $3.50
• Potential Upside/Downside: +831.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13 million
• Net Margins: -714.16%
• Pretax Margin: -712.70%
• Return on Equity: -122.44%
• Return on Assets: -88.40%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 1.15
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $1.27 million
• Price / Sales: 26.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 5.20

Miscellaneous

• Outstanding Shares: 79,685,000
• Free Float: 54,600,000
• Market Cap: $33.15 million
• Optionable: N/A
• Beta: 1.45